Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
pharmac erythropoietin
4
erythropoietin cancer
4
cancer patients
4
pharmac
1
cancer
1
patients
1
Similar Publications
New Zealand cancer patients should have access to erythropoietin treatment.
N Z Med J
May 2006
Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
Erythropoietin was the first haematopoietic growth factor to be cloned and put to clinical use in patients with anaemia. In New Zealand, the agent is approved and funded for patients with anaemia secondary to renal failure. Although there is Medsafe approval for its use in various other conditions, including cancer patients, it is not funded by Pharmac for these conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!